Literature DB >> 1088166

Therapeutic trials with levamisole and other agents in NZB/W mice.

A S Russell.   

Abstract

The effects of levamisole, ribovirin, and cyclophosphamide in preventing the spontaneous autoimmune disease of NZB/W mice have been evaluated. These drugs all had a significant effect, both in delaying mortality, and in postponing the development of antinuclear antibodies and proteinuria. Single-stranded DNA linked to IgG was also used but had no demonstrable effect. The results of therapeutic studies in murine lupus must be interpreted with caution in relation to the human disease, but as both levamisole and ribovirin are now being used in man, our results suggest that further studies with these drugs are warranted.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1088166

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Levamisole maintains cyclophsophamide-induced remission in murine lupus erythematosus.

Authors:  J Zulman; J Michalski; C McCombs; J Greenspan; N Talal
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

2.  Effect of levamisole on autologous rosette-forming cells in nude mice.

Authors:  J Van Wauwe; G Van Nijen
Journal:  Clin Exp Immunol       Date:  1977-12       Impact factor: 4.330

3.  Induction of interferon by levamisole and concanavalin A in HA/ICR and NZB/W mouse spleen cells.

Authors:  S K Tyring; S S Lefkowitz
Journal:  Experientia       Date:  1980-11-15

4.  Thiabendazole-induced suppression of renal damage in a murine model of autoimmune disease.

Authors:  S A Elgebaly; F Forouhar; P Dore-Duffy
Journal:  Am J Pathol       Date:  1984-05       Impact factor: 4.307

5.  Inhibition of lymphocyte proliferative responses by ribavirin.

Authors:  D L Peavy; W C Koff; D S Hyman; V Knight
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

6.  Condition-dependent immunoregulatory control of contact sensitivity by levamisole.

Authors:  D E Griswold; D T Walz
Journal:  Inflammation       Date:  1977-12       Impact factor: 4.092

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.